Januvia (sitagliptin) is an oral medication manufactured by Merck & Co. and used to treat type 2 diabetes. The drug was approved by the U.S. Food and Drug Administration (FDA) in 2006 and is one of the most popular type 2 diabetes drugs on the market. In 2007, the FDA approved a variation of Januvia called Janumet, which is a combination of sitagliptin and metformin and is also made by Merck.
Januvia is the top-selling brand in its class, and the drug allows Merck to tower above the competition with a 75 percent DPP-4 global market share with Januvia alone. In 2011, about 2 million prescriptions were written for the drug, and that number is expected to continue to climb in the coming years. Some analysts predict that as more people around the world are diagnosed with diabetes, annual sales of Januvia will reach $6 billion. Merck stands to benefit from the patent on the drug until 2022 and is developing a once-a-week version of Januvia. Januvia is now prescribed to be taken by mouth once a day.
In clinical trials Januvia proved to be effective in controlling blood sugar levels. However, there are also reports of serious side effects, including acute pancreatitis and pancreatic cancer, which caused Januvia users to file lawsuits against Merck. In litigation proceedings, plaintiffs accuse Merck of negligence and concealing the risks of these significant side effects.
How Does Januvia Work?
Januvia is designed to work with other type 2 diabetes medications, like Byetta, to increase their effectiveness. It is not meant to treat people with type 1 diabetes.
Januvia helps lower blood sugar in two ways. It helps the body increase insulin to stabilize blood sugar and decrease sugars that are made in the liver. It is a part of the class of diabetes medications called DPP-4 inhibitors. DPP-4 is a protein made by the body that plays a role in glucose metabolism.
The process works like this: After a person eats and blood sugar rises, hormones called incretin hormones are released from intestinal cells. Incretin stimulates pancreatic cells called beta cells to release insulin to metabolize sugar and signals the liver to stop making excess sugar. In people without diabetes, DPP-4 breaks down incretin to keep blood sugar and insulin levels balanced. For people with diabetes, too much sugar is already in the blood.
Januvia blocks DPP-4, allowing incretin to stay in the blood longer and to continue stimulating the pancreas into make more insulin to remove excess sugar. People who have excess ketones in the blood or urine – a condition known as diabetic ketoacidosis – should not take Januvia or Janumet.
Serious Side Effects
The most serious side effects associated with Januvia and Janumet are acute pancreatitis and pancreatic cancer. In 2011, the FDA received almost 200 reports of acute and chronic pancreatitis linked to Januvia and Janumet – some of which were fatal.
Pancreatitis is an inflammation of the pancreas. It can cause the body’s digestive enzymes to attack the pancreas. In severe cases, the disease can cause tissue damage, infection, cyst formation and bleeding. The damage can spread to other organs like the heart, kidneys and lungs, and the mortality rate is 10 to 30 percent.
|The symptoms of pancreatitis include:|
|Abdominal pain that may radiate to the back||Increased pain while eating or bending forward|
Cases of pancreatitis associated with Januvia and Janumet tend to be acute, meaning the disease occurs quickly and over a short period of time, and it can be fatal. A UCLA clinical study published in the journal Gastroenterology revealed that taking Januvia increases the risk of pancreatitis six-fold, and cases usually develop in less than two months.
Nearly 100 cases of acute pancreatitis caused by Januvia, including necrotizing pancreatitis, were reported to the FDA between 2006 and 2009. Necrotizing pancreatitis occurs when digestive hormones produced by the pancreas begin to digest the pancreatic tissue, and can lead to death.
In 2009, the FDA issued a safety alert that linked sitagliptin, the active ingredient in Januvia and Janumet, to acute pancreatitis. There were no safety studies conducted in people who have a history of pancreatitis, and the agency warned that it is not known whether these people are at an increased risk if they take sitagliptin. Pancreatitis can also lead to pancreatic cancer.
Januvia and Janumet are also linked to pancreatic cancer. Pancreatic tumors can grow without symptoms and may not be detected until the cancer reaches a later stage. People taking sitagliptin have more than double the risk of developing pancreatic cancer, according to the UCLA study. The risk of developing cancer increases the longer someone takes Januvia or Janumet.
Peter Butler, M.D., the study’s lead investigator, says that it can be difficult to discover the extent of the damage done to the pancreas without removing it and examining it. As a result, pancreatic cancer may be diagnosed late. The American Cancer Society says that the average rate of survival is 18 to 20 months, and the overall five-year survival rate is 4 percent.
|In addition to pancreatitis and pancreatic cancer, Januvia and Janumet are linked to a number of other side effects, including:|
|Elevated liver enzymes||Swelling of hands or legs|
|Headache||Upper respiratory infection|
|Stuffy or runny nose||Sore throat|
Side Effects of Janumet
Because Janumet is made with metformin, it carries a black-box warning about lactic acidosis. This condition occurs when metformin builds up in the blood and causes lactic acid to accumulate in the bloodstream. Symptoms of lactic acidosis include weakness and nausea. People who suffer from lactic acidosis should seek medical care immediately.
In addition, Januvia and Janumet increase the risk for kidney problems that may require dialysis.
Some people who took Januvia and Janumet suffered from severe side effects like pancreatitis and pancreatic cancer that may have led to death. As a result, patients and their families filed lawsuits against Merck.
Guy Riley filed a lawsuit on behalf of his wife Kathleen in October 2012. His lawsuit alleges that Merck and Amylin and Eli Lilly – the manufacturers of another diabetes drug also taken by Kathleen called Byetta – concealed their knowledge of dangerous side effects. Kathleen Riley began taking Januvia in 2006, and in 2009 she was diagnosed with pancreatic cancer. She later died from the disease.
Riley’s lawsuit claims that defendants failed to warn about side effects, and that despite knowing about the risk of pancreatic cancer, the drug manufacturers continued to aggressively market and sell defective products.
If you or a loved one took Januvia or Janumet and suffered from dangerous side effects like pancreatitis or pancreatic cancer, Drugwatch can help. Our patient advocates can answer your questions about treatment and explain your legal options.